- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03911531
Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops
November 21, 2023 updated by: Huda Al-Kouatly, Thomas Jefferson University
Brief Summary: Nonimmune hydrops fetalis (NIHF) is a potentially fatal condition characterized by abnormal fluid accumulation in two or more fetal compartments.
Numerous etiologies may lead to NIHF, and the underlying cause often remains unclear (1).
The current standard of genetic diagnostic testing includes a fetal karyotype and chromosomal microarray (CMA), with an option to pursue single gene testing on amniocytes collected by amniocentesis (2).
A large subgroup of the NIHF causes includes single gene disorders that are not diagnosed with the standard genetic workup for hydrops.
Currently, nearly 1 in 5 cases of NIHF is defined as idiopathic, meaning there is no identified etiology (2).
The investigators believe this is because the causes of NIHF are not completely investigated, specifically single gene disorders.
Our research study aims to increase the diagnostic yield by performing whole exome sequencing (WES) and whole genome sequencing (WGS) on prenatal and neonatal NIHF cases when standard genetic testing is negative, identifying known and new genes, thus providing vital information to families regarding the specific diagnosis and risk to future pregnancies.
The investigators plan to perform WES as the initial diagnostic test.
If WES is negative, then the investigators will proceed to perform WGS.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This is a prospective cohort study design for fetuses or neonates affected with NIHF.
Mother-father-fetus trios of pregnancies complicated by idiopathic non-immune fetal hydrops will be identified.
These patients will be counseled by a Maternal-Fetal Medicine specialist as would be the routine.
As part of the routine work-up, amniocentesis will be recommended for karyotype, CMA and an infectious work-up.
Amniocentesis will be performed by the Maternal-Fetal Medicine specialist of the referring institution.
The patient will also be offered genetic counseling (routine).
Subjects will be offered enrollment when inclusion criteria are met.
After enrollment, the following samples will be collected: (1) maternal blood (2) paternal blood, (3) fetal DNA isolated from amniocytes (4) neonatal blood when referral is done postnatally.
The WES results will be reported to the genetic counselor dedicated to the study.
The parents will be contacted by the genetic counselor and counseled on the findings whether they were positive or negative.
The result will also be communicated to the patient's primary MFM provider or pediatrician and appropriate referrals to pediatric genetics specialists will be made by the primary provider.
In cases where no genetic disorder is identified, the sample will be stored and then subsequently whole genome sequencing will be performed.
Study Type
Observational
Enrollment (Estimated)
55
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Huda B Al-Kouatly, MD
- Phone Number: 215-955-9200
- Email: Huda.Al-kouatly@jefferson.edu
Study Contact Backup
- Name: Stephanie M Rice, MS
- Email: stephanie.rice@jefferson.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 53 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients will be recruited from MFM physicians, paediatricians,and neonatologists.
Description
The following inclusion criteria will apply:
- Fetal hydrops identified anytime in pregnancy after the first trimester
- Parents are planning to proceed with amniocentesis as a routine workup for hydrops.
- Both parents are available for blood sample collection
- Normal CMA and normal karyotype if performed
- Negative workup for Parvovirus B19, cytomegalovirus, toxoplasmosis, and syphilis
- Negative fetomaternal hemorrhage workup as a cause for hydrops For cases of neonatal hydrops, the criteria for invasive prenatal testing will not be required as a postnatal blood sample from the hydropic infant will be the source of proband DNA.
The following exclusion criteria will apply:
- Microarray was abnormal or karyotype was abnormal
- Hydrops caused by congenital infection
- Fetomaternal hemorrhage was a documented etiology for hydrops
- Parental DNA cannot be obtained for either parents
- Donor egg or donor sperm were utilized for conception
- Fetus/Infant diagnosed with lysosomal storage disease
- Pregnant woman or father of the baby less than 16 years of age
- Hydrops was diagnosed concomitantly with intrauterine fetal demise
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Fetuses
DNA obtained from amniotic fluid samples
|
Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions.
WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
|
Neonates
DNA obtained from neonatal blood samples
|
Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions.
WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identify known single gene disorders that would not be detected by microarray as a cause of nonimmune fetal hydrops by performing whole exome sequencing (WES)
Time Frame: 5 years
|
5 years
|
Identify novel genetic disorders associated with nonimmune hydrops
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the incremental value of whole genome sequencing (WGS) in the evaluation of fetal hydrops when WES is negative
Time Frame: 5 years
|
5 years
|
Better counsel the parents about the etiology of hydrops especially if they desire a subsequent pregnancy
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Huda B Al-Kouatly, MD, Thomas Jefferson University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Whybra C, Mengel E, Russo A, Bahlmann F, Kampmann C, Beck M, Eich E, Mildenberger E. Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF): more common than assumed? Report of four cases with transient NIHF and a review of the literature. Orphanet J Rare Dis. 2012 Nov 8;7:86. doi: 10.1186/1750-1172-7-86.
- Lionel AC, Costain G, Monfared N, Walker S, Reuter MS, Hosseini SM, Thiruvahindrapuram B, Merico D, Jobling R, Nalpathamkalam T, Pellecchia G, Sung WWL, Wang Z, Bikangaga P, Boelman C, Carter MT, Cordeiro D, Cytrynbaum C, Dell SD, Dhir P, Dowling JJ, Heon E, Hewson S, Hiraki L, Inbar-Feigenberg M, Klatt R, Kronick J, Laxer RM, Licht C, MacDonald H, Mercimek-Andrews S, Mendoza-Londono R, Piscione T, Schneider R, Schulze A, Silverman E, Siriwardena K, Snead OC, Sondheimer N, Sutherland J, Vincent A, Wasserman JD, Weksberg R, Shuman C, Carew C, Szego MJ, Hayeems RZ, Basran R, Stavropoulos DJ, Ray PN, Bowdin S, Meyn MS, Cohn RD, Scherer SW, Marshall CR. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med. 2018 Apr;20(4):435-443. doi: 10.1038/gim.2017.119. Epub 2017 Aug 3.
- Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Nemeth AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sorensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet. 2015 Jul;47(7):717-726. doi: 10.1038/ng.3304. Epub 2015 May 18.
- Raymond M, Critchlow E, Rice SM, Wodoslawsky S, Berger SI, Hegde M, Empey PE, Al-Kouatly HB. Fetal pharmacogenomics: A promising addition to complex neonatal care. Mol Genet Metab. 2022 Sep-Oct;137(1-2):140-145. doi: 10.1016/j.ymgme.2022.08.002. Epub 2022 Aug 12.
- Society for Maternal-Fetal Medicine (SMFM); Norton ME, Chauhan SP, Dashe JS. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol. 2015 Feb;212(2):127-39. doi: 10.1016/j.ajog.2014.12.018. Epub 2014 Dec 31.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2019
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
April 9, 2019
First Submitted That Met QC Criteria
April 9, 2019
First Posted (Actual)
April 11, 2019
Study Record Updates
Last Update Posted (Estimated)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 21, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB18D.728
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genetic Disorders
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchCompleted
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGenetic DisorderUnited States
-
YehCompletedFertility Disorders | Genetic Disorder | Reproductive Disorder
-
BioMarin PharmaceuticalUnknownRare Genetic DisordersUnited States
-
University Hospital, Strasbourg, FranceUnknownGenetic Disorders in PregnancyFrance
-
Kaiser PermanenteNational Human Genome Research Institute (NHGRI)CompletedGenetic DisordersUnited States
-
Abbott MolecularUnknown
-
Boston Children's HospitalRecruitingGenetic Predisposition to Disease | Genetic Disease | Development, Infant | Genetic Syndrome | Development, ChildUnited States
-
Rady Pediatric Genomics & Systems Medicine InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingGenetic Diseases | Genetic Syndrome | Mendelian DisordersUnited States
-
Second Affiliated Hospital, School of Medicine,...CompletedPlasma microRNA in Patients With Genetic Susceptibility to Mental Disorders
Clinical Trials on Whole Exome Sequencing
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedMetabolism, Inborn Errors | Hearing Loss | Hereditary DiseaseUnited States
-
Children's Hospital of Fudan UniversityNot yet recruitingDiarrhea, Infantile | Enteropathy
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Sensor Technology for DeafblindCentral Clinical Hospital under President Affairs; Deaf-Blind Support Foundation... and other collaboratorsCompletedRetinitis Pigmentosa | Usher SyndromesRussian Federation
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanUnknownAcute Disease | Congenital Metabolic DisorderTaiwan
-
Boston Children's HospitalNational Eye Institute (NEI)RecruitingStrabismus | Nystagmus, CongenitalUnited States
-
Hospices Civils de LyonRecruiting
-
Institute of Child HealthUniversity College, London; Great Ormond Street Hospital for Children NHS Foundation...RecruitingAlternating Hemiplegia of Childhood | ATP1A3-related Disease | Rapid Onset Dystonia Parkinsonism | CAPOSUnited Kingdom
-
Mansoura UniversityActive, not recruiting
-
Copenhagen University Hospital at HerlevRecruiting